Bacteriocins: perspective for the development of novel anticancer drugs

Baindara, Piyush; Korpole, Suresh; Grover, Vishakha

doi:10.1007/s00253-018-9420-8

Cited by 91 publications

(53 citation statements)

References 198 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These small cationic molecules (30-60 amino acids), due to their amphiphilic helices, differ in their spectrum of activity, mode of action, molecular weight, and biochemical properties. A large portion of Gram-negative bacteriocins resemble eukaryotic antimicrobial peptides such as defensins [7]. These toxic peptides are classified according to their biosynthetic mechanisms as either ribosomally synthesized peptides demonstrating a quite narrow range of antimicrobial activity, and non-ribosomally synthesized peptides demonstrating a wider range of activity towards bacteria or fungi [8].…”

Section: Bacteriocinsmentioning

confidence: 99%

“…Specifically, the findings of Ghoul et al show a lower bacteriocin diversity correlating with the ability of P. aeruginosa to persist in infections of the CF lung coupled with several immunity systems present in this species [43]. Nisin variants are currently being implemented as antibacterial sanitizers to control pathogenic Staphylococcus and Streptococcus species associated with mastitis in lactating cows [7]. Research using recombinant PCR techniques to integrate enterocin CRL35 and microcin V genes, producing the combined bacteriocin Ent35-MccV allowed for activity against clinically isolated enterohemorrhagic E. coli and Listeria monocytogenes, amongst other pathogens [22].…”

Section: Infectious Diseasementioning

confidence: 99%

“…Bacteriocins with anticancer activity appear to be cationic, amphiphilic and membrane active with cytoxicity due to necrotic cell membrane lysis induced by increased presence of negatively charged molecules on the membrane surface [7]. Additionally, cancer cells have higher membrane fluidity compared to normal cells allowing for membrane destabilization [46].…”

Section: Anti-cancer Activitymentioning

confidence: 99%

See 2 more Smart Citations

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Slattery²,

2020

View full text Add to dashboard Cite

Despite highly specialized international interventions and policies in place today, the rapid emergence and dissemination of resistant bacterial species continue to occur globally, threatening the longevity of antibiotics in the medical sector. In particular, problematic nosocomial infections caused by multidrug resistant Gram-negative pathogens present as a major burden to both patients and healthcare systems, with annual mortality rates incrementally rising. Bacteriocins, peptidic toxins produced by bacteria, offer promising potential as substitutes or conjugates to current therapeutic compounds. These non-toxic peptides exhibit significant potency against certain bacteria (including multidrug-resistant species), while producer strains remain insusceptible to the bactericidal peptides. The selectivity and safety profile of bacteriocins have been highlighted as superior advantages over traditional antibiotics; however, many aspects regarding their efficacy are still unknown. Although active at low concentrations, bacteriocins typically have low in vivo stability, being susceptible to degradation by proteolytic enzymes. Another major drawback lies in the feasibility of large-scale production, with these key features collectively limiting their current clinical application. Though such limitations require extensive research, the concept of expanding bacteriocins from food preservation to human health opens many fascinating doors, including novel drug delivery systems and anticancer treatment applications.

show abstract

Section: Bacteriocinsmentioning

confidence: 99%

Section: Infectious Diseasementioning

confidence: 99%

Section: Anti-cancer Activitymentioning

confidence: 99%

See 1 more Smart Citation

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Slattery²,

2020

View full text Add to dashboard Cite

show abstract

“…The use of bacteria or their products against cancer has already been tested at different levels. For instance, a treatment with mixed extracts from Streptococcus pyogenes and Serratia marscensces (currently known as Coley toxins) on unresectable tumors was successfully administrated more than 100 years ago (Karpiński and Adamczak, 2018; reviewed in Baindara et al, 2018;Ashu et al, 2019). Similarly, the study of different bacteriocins and their antineoplasic properties has a long history and has included colicins, pyocins, pediocins, and microcins (reviewed in Lagos, 2007;Cornut et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

“…Similarly, the study of different bacteriocins and their antineoplasic properties has a long history and has included colicins, pyocins, pediocins, and microcins (reviewed in Lagos, 2007;Cornut et al, 2008). Over the past few years there has been a renewed interest in exploring anticancer properties of other bacteriocins, and among them are laterosporulin10 (Baindara et al, 2017), nisin ZP (Kamarajan et al, 2015), nisin (Joo et al, 2012), plantaricin P1053 (De Giani et al, 2019), and others (reviewed in Kaur and Kaur, 2015;Baindara et al, 2018;Karpiński and Adamczak, 2018;Ashu et al, 2019). Microcins are a class of bacteriocins with a molecular mass of <10 kDa produced by Gram-negative bacteria, principally Enterobactericeae.…”

Section: Introductionmentioning

confidence: 99%

Exploiting Zebrafish Xenografts for Testing the in vivo Antitumorigenic Activity of Microcin E492 Against Human Colorectal Cancer Cells

et al. 2020

View full text Add to dashboard Cite

One of the approaches to address cancer treatment is to develop new drugs not only to obtain compounds with less side effects, but also to have a broader set of alternatives to tackle the resistant forms of this pathology. In this regard, growing evidence supports the use of bacteria-derived peptides such as bacteriocins, which have emerged as promising anti-cancer molecules. In addition to test the activity of these molecules on cancer cells in culture, their in vivo antitumorigenic properties must be validated in animal models. Although the standard approach for such assays employs experiments in nude mice, at the initial stages of testing, the use of high-throughput animal models would permit rapid proof-of-concept experiments, screening a high number of compounds, and thus increasing the possibilities of finding new anti-cancer molecules. A validated and promising alternative animal model are zebrafish larvae harboring xenografts of human cancer cells. Here, we addressed the anti-cancer properties of the antibacterial peptide microcin E492 (MccE492), a bacteriocin produced by Klebsiella pneumoniae, showing that this peptide has a marked cytotoxic effect on human colorectal cancer cells in vitro. Furthermore, we developed a zebrafish xenograft model using these cells to test the antitumor effect of MccE492 in vivo, demonstrating that intratumor injection of this peptide significantly reduced the tumor cell mass. Our results provide, for the first time, evidence of the in vivo antitumoral properties of a bacteriocin tested in an animal model. This evidence strongly supports the potential of this bacteriocin for the development of novel anti-cancer therapies.

show abstract

Bacteriocins of Probiotics as Potent Anticancer Agents

Sharma

Tiwari

2020

Probiotic Research in Therapeutics

View full text Add to dashboard Cite

Bacteriocins: perspective for the development of novel anticancer drugs

Cited by 91 publications

References 198 publications

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Bacteriocins, Potent Antimicrobial Peptides and the Fight against Multi Drug Resistant Species: Resistance Is Futile?

Exploiting Zebrafish Xenografts for Testing the in vivo Antitumorigenic Activity of Microcin E492 Against Human Colorectal Cancer Cells

Bacteriocins of Probiotics as Potent Anticancer Agents

Contact Info

Product

Resources

About